Yacella 0.03mg/3mg Tablets

Country: United Kingdom

Language: English

Source: myHealthbox

Active ingredient:

ethinylestradiol, drospirenone

Available from:

Morningside Healthcare Limited

ATC code:

G03AA12

INN (International Name):

ethinylestradiol, drospirenone

Dosage:

0.03mg/3mg

Pharmaceutical form:

Tablets

Administration route:

Oral use

Units in package:

Pack sizes: 21 tablets 3x21 tablets 6x21 tablets 13x21 tablets

Prescription type:

POM - Prescription Only Medicine

Manufactured by:

Morningside Pharmaceutical Limited

Therapeutic group:

Progestogens and estrogens, fixed combinations

Therapeutic indications:

Oral contraception.

Authorization status:

Authorised

Authorization date:

2015-03-09

Patient Information leaflet

Artwork No.
Customer
Description
Market
Language
Size
Min. Font Size
Page No.
Version No.
Date
Software
251114/3
Morningside
Yacella 0.03 mg/3 mg Pil
UK
English
860 x 430 mm
10 pt
1 of 2
10
01-04-15
Coreldraw 12
Packaging Development
Quality Assurance (QA)
Quality Control (QC)
Production
e-mail : [e-mail]
Ph : [phone]
Colours Used
Black
Keyline
CLEARLY MARK ANY AMENDMENTS ON ONE PROOF AND RETURN TO  ARTWORK CREATIVE DESIGN.
Your Artwork/Disk has been translated through our Digital Artwork System into a format compatible with that of the litho Printing Process.
WARNING! We cannot accept responsibility for any errors in this proof after approval. The artwork received has been significantly adjusted, revised or reset by 
us from disk or hard copy. Whilst we take extreme care at all times to ensure accuracy, the final responsibility must be taken by our customer. 
If you sign this proof you are signifying full approval of design and text.
Non Printing Area
Non Printing Area
Non Printing Area
Non Printing Area
Non Printing Area
Non Printing Area
Non Printing Area
Non Printing Area
READ  ALL  OF  THIS  LEAFLET  CAREFULLY  BEFORE  YOU  START  TAKING  THIS  MEDICINE  BECAUSE  IT  CONTAINS  IMPORTANT 
INFORMATION FOR YOU.
Keep this leaflet. You may need to read it again.
If you have any further questions, ask your doctor or pharmacist.
This medicine has been prescribed for you only. Do not pass it
on to others. It may harm them, even if their 
signs of illness are the same as yours.
If you get any side effect, talk to your doctor, or pharmacist or nurse. This includes any possible side effects not 
listed in this leaflet.
IMPORTANT THINGS TO KNOW ABOUT COMBINED HORMONAL CONTRACEPTIVES (CHCS): 
They are one of the most reliable reversible methods of contraception if us

Summary of Product characteristics

SUMMARY OF PRODUCT CHARACTERISTICS 

1 
NAME OF THE MEDICINAL PRODUCT 
Yacella 0.03 mg/3 mg Tablets  

2 
QUALITATIVE AND QUANTITATIVE COMPOSITION 
Each tablet contains 0.03 mg ethinylestradiol and 3
mg drospirenone.  
Excipients with known effect: 
Each tablet contains 72 mg of lactose, 0.032 mg of E110,
susnset yellow FCF 
and 0.12 mg of E102, tartrazine. 
For a full list of excipients, see section 6.1  

3 PHARMACEUTICAL 
FORM 
Tablet  
Round, yellow, uncoated biconvex tablet with ‘143’ debossed on
one side and 
other side plain. 

4 CLINICAL 
PARTICULARS 

4.1 THERAPEUTIC 
INDICATIONS 
Oral contraception. 
The decision to prescribe Yacella Tablets should take into
consideration the 
individual woman’s current risk factors, particularly those for
venous 
thromboembolism (VTE), and how the risk of VTE with Yacella Tablets 
compares with other CHCs (see sections 4.3 and 4.4). 

4.2 
POSOLOGY AND METHOD OF ADMINISTRATION 
Route of administration: oral use 
HOW TO TAKE YACELLA TABLETS 
The tablets must be taken every day at about the same time, if
necessary with a 
little liquid, in the order shown on the blister
pack. One tablet is to be taken 
daily for 21 consecutive days. Each subsequent pack is started after
a 7-day 
tablet-free interval, during which time a withdrawal bleed
usually occurs. This 
usually starts on day 2-3 after the last tablet and may not have
finished before 
the next pack is started. 
HOW TO START YACELLA TABLETS 

No preceding hormonal contraceptive use (in the past month) 
Tablet-taking has to start on day 1 of the woman’s natural
cycle (i.e. the first 
day of her menstrual bleeding). 
•

Changing from a combined hormonal contraceptive (combined oral 
contraceptive (COC), vaginal ring, or transdermal patch) 
The woman should start with Yacella Tablets preferably on the
day after 
the last active tablet (the last tablet con